Source: Life Site News Author: Calvin Freiburger

Three Republican senators sent a letter to U.S. Food & Drug Administration (FDA) Commissioner Alex Azar this month demanding an explanation as to why the agency revoked its approval of hydroxychloroquine (HCQ), a drug that has shown promise in treating COVID-19.

HCQ has long been approved for use in treating malaria, arthritis, and certain autoimmune conditions, but its potential applications to COVID-19 became a political lightning rod after President Donald Trump first called attention to early studies indicating its potential. The FDA initially issued an Emergency Use Authorization (EUA) allowing it to be distributed from the Strategic National Stockpile (SNS) but revoked that authorization in June, claiming “new information” indicated the potential dangers outweighed any potential effectiveness.

“We have heard from licensed physicians” who have detailed “how this decision has affected their ability to treat patients” and “led to misinformation and confusion across the country,” read the August 18 letter by Sens. Ron Johnson of Wisconsin, Mike Lee of Utah, and Ted Cruz of Texas. Some states, the letter warned, have used the FDA’s decision as justification to ban doctors from prescribing HCQ off-label with patients’ informed consent, which was a “longstanding and established authority” they previously enjoyed.

“The licensed physicians we have heard from stressed the potential benefits of early outpatient treatment of HCQ for individuals infected with COVID-19,” the letter continued. These physicians have pointed to the low mortality rates in other countries — like India, Turkey, South Korea, and Morocco — that are using HCQ widely on outpatient populations before the disease progresses to more lethal stages of the virus that require hospitalization.

“However, the physicians are concerned that the FDA’s actions regarding HCQ may be directly costing lives by limiting outpatient access to this potentially beneficial treatment,” the senators warned.

The letter asks the FDA to provide the Senate with the studies influencing its decision, detail what steps it has taken (if any) to make available in the United States other COVID-19 treatments currently being used internationally, and any public statements the agency has made “to clarify that the FDA does not regulate the practice of medicine and that state governments may not regulate the sale or prohibit the sale of prescription drugs.”

In the early days of the COVID-19 outbreak, scientists began researching HCQ’s potential applications in treating the new virus. But after Trump started promoting it, partisans in media and government began a push to discredit the drug, from outlandish stories about a man who died after drinking fish tank cleaner to a junk study falsely claiming HCQ killed Veterans Administration patients.

One influential study published by The Lancet in May purported to not only find “no benefit” to using HCQ, but instead finding “decreased in-hospital survival and an increased frequency of ventricular arrhythmias,” leading several countries to ban it. However, that study was retracted upon the discovery that the company that provided its data was very likely fraudulent.

“There’s no question that in the people who need to be treated, and are treated early, (hydroxychloroquine) has a very substantial benefit in reducing risk of hospitalization or mortality,” Yale School of Public Health epidemiologist Dr. Harvey Risch told conservative radio host Mark Levin last week.

“People need to be writing or calling their congressmen and senators and complaining that this is not the way the country should work,” Risch added. “A bureaucracy that’s in bed with other forces that are causing them to make decisions that are not based on the science — that is killing Americans.”

Related: GOP senators push FDA for answers on hydroxychloroquine

US Senators request HCQ decision information from FDA’s Stephen Hahn

New Jersey lawmaker bangs the drum for hydroxychloroquine

Yale prof: “The evidence in favor of hydroxychloroquine benefit in high-risk patients treated early as outpatients is stronger than anything else I’ve ever studied.”

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »